FDA Brief

Warning letters Food

FDA warning letter to

Wholly Liquid Nutritional Supplements LLC

LowIssued Dec 9, 2021Posted Dec 21, 2021Office of Human and Animal Food Operations East – Division 1

FDA says Wholly Liquid’s supplement website claims make seven products unapproved new drugs and misbranded.

What happened

FDA reviewed the company’s website in November and December 2021 and its Facebook page. It found claims that SpiroLaze, BioLaze, LiquiLaurin, Vit-B12, DeStress, Omega Plus, and Ionized Silver treat or prevent diseases such as Lyme disease, infections, depression, cancer, and Alzheimer’s. FDA says this makes them unapproved new drugs and misbranded because they lack adequate directions for use.

What FDA found

  1. The company’s website and Facebook claims show the products are intended to treat or prevent diseases, making them drugs.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The products are unapproved new drugs because FDA has not approved them for these disease uses.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for safe use by a layperson for these serious diseases.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded products in interstate commerce violates the FD&C Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to address the violations, including how it will prevent recurrence and related documentation. If it cannot finish, it must explain why and give a completion date.

Who should pay attention

  • dietary supplement brands making disease claims
  • retailers and online marketplaces selling supplement products
  • consumers using Lyme or immune-support products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk